Clinical Effect of Postoperative Application of Ticagrelor after Percutaneous Coronary Stent Implantation in Patients with Acute Coronary Syndrome
LI Ai-gui
Abstract：Objective:To investigate the clinical effect of Ticagrelor in patients with acute coronary syndrome(ACS) after percutaneous coronary stent implantation(PCI).Method:126 cases of ACS patients in our hospital from January 2014 to April 2015 were selected and divided into the control group and the observation group by using the odd even grouping method.The control group was treated with Clopidogrel,the observation group was treated with Ticagrelor.The platelet inhibition rate of before treatment and 3 d,7 d and 14 d after treatment were compared between the two groups.All patients were followed up for 1 year. The incidence of bleeding events,adverse events and adverse reactions were compared between the two groups.Result:3 d,7 d and 14 d after treatment,the platelet inhibition rates of the observation group were (58.8±6.3)%,(83.9±6.7)%,(85.2±7.3)%,the control group were (35.8±5.9)%,(58.1±6.2)%, (59.7±6.8)%,which were significantly better than before treatment,and the platelet inhibition rates of the patients in the observation group each period after treatment were significantly better than the control group,the differences were statistically significant(P<0.05).The incidence rates of bleeding and adverse events in the observation group were 17.46% and 7.94%,in the control group they were 15.87% and 9.52%,the differences were not statistically significant(P>0.05).The incidence of recurrent angina in the control group was 9.52%,the observation group had no recurrence of angina pectoris patients,but in the observation group the incidence rate of dyspnea was 6.35% and the control group had no respiratory distress,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of other adverse events(P>0.05).Conclusion:Ticagrelor for patients with ACS after PCI can significantly increase platelet inhibition rate,and can reduce the incidence rate of adverse events,but it has a higher probability of occurrence of dyspnea,therefore its clinical use shall be considered with caution in order to reduce the occurrence of adverse events.
Keywords：Acute coronary syndromePercutaneous coronary stent implantationTicagrelor
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：2( 3-4 )